<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02605525</url>
  </required_header>
  <id_info>
    <org_study_id>181501</org_study_id>
    <nct_id>NCT02605525</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of SM101 in the Treatment of IgA Nephropathy</brief_title>
  <official_title>A Phase 2 Study to Assess the Efficacy and Safety of Intravenous Infusion With Human Soluble Recombinant Fc-gamma Receptor IIB (SM101/BAX 1810) in Subjects With Immunoglobulin A Nephropathy (IgAN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baxalta now part of Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy and safety of SM101 in the treatment of
      Immunoglobulin A nephropathy (IgAN)
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">November 2016</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change in proteinuria from Baseline to Week 24</measure>
    <time_frame>Baseline and Week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants who demonstrate a ≥30% reduction from Baseline in proteinuria</measure>
    <time_frame>Baseline, Week 8, Week 12, Week 18, and Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who reach and maintain proteinuria levels below 1.0 g/24 h</measure>
    <time_frame>Week 8, Week 12, Week 18, and Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline in Estimated glomerular filtration rate (eGFR)</measure>
    <time_frame>Baseline, Week 8, Week 12, Week 18, and Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who experience any treatment-related serious adverse event (SAE) or severe adverse events (AE) during the course of the treatment period or subsequent follow-up period</measure>
    <time_frame>Throughout the study period of approximately 19 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who experience serious adverse events (SAEs) or adverse events (AEs)</measure>
    <time_frame>Throughout the study period of approximately 19 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who experience temporally-related adverse events (AEs)</measure>
    <time_frame>Baseline through 72 hours of IP administration</time_frame>
    <description>Temporally-related AEs - defined as AEs occurring during investigational product (IP) administration or within 72 hours of IP administration, regardless of causality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with any clinically significant change in vital signs during investigational product (IP) administration or within 30 minutes following administration</measure>
    <time_frame>Baseline through 30 minutes following IP administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of infusions associated with adverse events (AEs) or serious adverse events (SAEs) , regardless of causality</measure>
    <time_frame>Throughout the study period of approximately 19 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of infusions that had to be slowed, interrupted, or terminated due to adverse events (AEs) or serious adverse events (SAEs)</measure>
    <time_frame>Throughout the study period of approximately 19 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with detectable levels of antidrug antibodies (ADAs)</measure>
    <time_frame>Baseline, Week 3, Week 4, Week 12, Week 24, or early termination from the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant abnormal laboratory assessments</measure>
    <time_frame>Throughout the study period of approximately 19 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: maximum observed concentration (Cmax)</measure>
    <time_frame>Week 1 within 30 minutes pre-infusion, and post-infusion 0.5, 1, 2, 4, 8 or 12, 24, 48 or 72, and 168 hours. Week 4 within 30 minutes pre-infusion, and post-infusion 0.5, 1, 2, 4, 24, and 168 hours.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: time of maximum observed concentration (Cmax)</measure>
    <time_frame>Week 1 within 30 minutes pre-infusion, and post-infusion 0.5, 1, 2, 4, 8 or 12, 24, 48 or 72, and 168 hours. Week 4 within 30 minutes pre-infusion, and post-infusion 0.5, 1, 2, 4, 24, and 168 hours.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: area under the concentration-time curve during a dosing interval (AUC(0-tau))</measure>
    <time_frame>Week 1 within 30 minutes pre-infusion, and post-infusion 0.5, 1, 2, 4, 8 or 12, 24, 48 or 72, and 168 hours. Week 4 within 30 minutes pre-infusion, and post-infusion 0.5, 1, 2, 4, 24, and 168 hours.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: terminal half-life (t1/2)</measure>
    <time_frame>Week 1 within 30 minutes pre-infusion, and post-infusion 0.5, 1, 2, 4, 8 or 12, 24, 48 or 72, and 168 hours. Week 4 within 30 minutes pre-infusion, and post-infusion 0.5, 1, 2, 4, 24, and 168 hours.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: systemic clearance (CL)</measure>
    <time_frame>Week 1 within 30 minutes pre-infusion, and post-infusion 0.5, 1, 2, 4, 8 or 12, 24, 48 or 72, and 168 hours. Week 4 within 30 minutes pre-infusion, and post-infusion 0.5, 1, 2, 4, 24, and 168 hours.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: volume of distribution at the terminal phase (Vz)</measure>
    <time_frame>Week 1 within 30 minutes pre-infusion, and post-infusion 0.5, 1, 2, 4, 8 or 12, 24, 48 or 72, and 168 hours. Week 4 within 30 minutes pre-infusion, and post-infusion 0.5, 1, 2, 4, 24, and 168 hours.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: volume of distribution at steady state (Vss)</measure>
    <time_frame>Week 1 within 30 minutes pre-infusion, and post-infusion 0.5, 1, 2, 4, 8 or 12, 24, 48 or 72, and 168 hours. Week 4 within 30 minutes pre-infusion, and post-infusion 0.5, 1, 2, 4, 24, and 168 hours.</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Immunoglobulin A Nephropathy</condition>
  <arm_group>
    <arm_group_label>SM101 12 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Human soluble recombinant Fcγ Receptor IIB</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SM101 24 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Human soluble recombinant Fcγ Receptor IIB</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>L-histidine-buffered saline with mannitol, sucrose, and polysorbate 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SM101</intervention_name>
    <description>Human soluble recombinant Fcγ Receptor IIB</description>
    <arm_group_label>SM101 24 mg/kg</arm_group_label>
    <arm_group_label>SM101 12 mg/kg</arm_group_label>
    <other_name>BAX1810</other_name>
    <other_name>BAX 1810</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>L-histidine-buffered saline with mannitol, sucrose, and polysorbate 20</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18 years of age or older at the time of screening

          2. Participant may be of any race or ethnicity

          3. Participant must have a biopsy-proven diagnosis of IgAN.

          4. Participant's blood pressure is ≤130/80 mmHg at Screening

          5. Participant is on maximally tolerated dose of an angiotensin-converting enzyme (ACE)
             inhibitor and/or angiotensin receptor blocker (ARB) for at least 3 months prior to the
             baseline visit.

          6. Participant must present at screening with current proteinuria levels between 1 g/24 h
             and 3.5 g/24 h, based on spot urine protein-to-creatinine ratio (UPCR)

          7. Participant must present at screening with an estimated glomerular filtration rate
             (eGFR) &gt;40mL/min/1.73m^2

          8. If a female of childbearing potential, participant must have a negative pregnancy test
             at screening, is not currently breastfeeding, and agrees to employ adequate birth
             control measures for the duration of the study. Male participants with female partners
             of childbearing potential must agree to use adequate birth control measures for the
             duration of the study

          9. Participant is willing and able to comply with the requirements of this protocol and
             agrees to sign an informed consent form prior to any study-related activities

        Exclusion Criteria:

          1. Participant has a history or current evidence of renal disease other than IgAN

          2. Participants with evidence of rapidly progressive disease

          3. Participant has IgAN with histologic evidence of advanced tubular atrophy and
             interstitial

          4. History or current evidence of other autoimmune disease

          5. History or current evidence of any chronic or uncontrolled medical condition which
             could, in the opinion of the Investigator, affect the participant's safety and ability
             to adhere to this protocol

          6. History or current evidence of a severe acute or chronic infection

          7. Use of systemic corticosteroids within 3 months prior to baseline, or anticipated use
             during the treatment period (Week 1 through Week 4). Note: Corticosteroids
             administered by inhalation or intranasally, or limited topical use of low-potency
             topical corticosteroids are allowed throughout the study.

          8. Known hypersensitivity or allergic reaction to any E. coli-derived recombinant
             product, yeast extract, or to the IP or any of its excipients

          9. Treatment with any immunomodulatory/immunosuppressive compound or monoclonal antibody
             for any indication within 6 months (unless otherwise stated) prior to screening (eg, B
             cell-depleting agents [eg, rituximab, epratuzumab] for ≥48 weeks; B-cell modifying
             agents [eg, belimumab, atacicept] for ≥24 weeks; IV immunoglobulins for ≥12 weeks and
             all other immunosuppressive treatments [eg, methotrexate, cyclophosphamide,
             cyclosporine, tacrolimus, mycophenolate mofetil, azathioprine] for ≥12 weeks)

         10. Clinically significant laboratory abnormalities prior to baseline

         11. History of any malignancy within past 5 years prior to screening (except for basal and
             squamous cell carcinomas of the skin, in situ cervical cancer, and stable prostate
             cancer that does not require treatment)

         12. History of tonsillectomy within 2 months prior to screening

         13. Participation in another clinical study involving an IP or investigational device
             within 30 days prior to screening or is scheduled to participate in another clinical
             study involving an IP or investigational device during the course of this study

         14. Participant is a family member or employee of the Investigator

         15. A female participant who is pregnant or nursing at the time of screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Gelmont, MD</last_name>
    <role>Study Director</role>
    <affiliation>Shire</affiliation>
  </overall_official>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 12, 2015</study_first_submitted>
  <study_first_submitted_qc>November 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2015</study_first_posted>
  <last_update_submitted>October 19, 2017</last_update_submitted>
  <last_update_submitted_qc>October 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IgAN</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Glomerulonephritis, IGA</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

